Iterum Therapeutics notifies Nasdaq of delisting

Iterum Therapeutics plc notified Nasdaq of the removal of its Ordinary Shares from listing and/or registration on the Nasdaq Stock Market LLC pursuant to Form 25 and the cited rules 17 CFR 240.12d2-2.

Rhea-AI Filing Summary

Iterum Therapeutics plc notified Nasdaq of the removal of its Ordinary Shares from listing and/or registration on the Nasdaq Stock Market LLC pursuant to Form 25 and the cited rules 17 CFR 240.12d2-2. The Exchange certified compliance with its procedures for withdrawal.

Key Figures

Commission File Number: 333-224582 Cited Rule: 17 CFR 240.12d2-2 Expires: March 31, 2018 +1 more

4 metrics

Commission File Number 333-224582 Form 25 cover filing identifier

Cited Rule 17 CFR 240.12d2-2 Regulatory provision governing removal/withdrawal

Expires March 31, 2018 form header expiration date

Issuer telephone 312-778-6070 Issuer principal office contact

Key Terms

Form 25, 17 CFR 240.12d2-2, voluntary withdrawal

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(a)(1)"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

voluntary withdrawal regulatory

"the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Iterum Therapeutics (ITRMF) file a Form 25 with Nasdaq?

The filing notifies Nasdaq of the removal of Iterum Therapeutics plc Ordinary Shares from listing and/or registration. It cites compliance with 17 CFR 240.12d2-2 and states both the Exchange and issuer complied with rules governing voluntary withdrawal.

Does the Form 25 mean Iterum (ITRMF) is delisting by force or voluntarily?

The Form 25 states the withdrawal was processed under 17 CFR 240.12d2-2(c), indicating the issuer complied with Exchange rules governing voluntary withdrawal. The Exchange certified it followed its procedures for striking the class from listing.

Who certified the removal of Iterum Therapeutics (ITRMF) from Nasdaq?

Nasdaq Stock Market LLC certified the removal and caused the notification to be signed on its behalf by Aravind Menon, Hearings Advisor. The filing affirms Nasdaq had reasonable grounds to file Form 25 and that procedural requirements were met.

What securities class did Iterum Therapeutics (ITRMF) remove from Nasdaq?

The Form 25 identifies the class as Ordinary Shares. The Exchange states it struck that class from listing and/or withdrew its registration on Nasdaq in accordance with the cited regulatory provisions.

Does the Form 25 disclose timing or next steps for Iterum (ITRMF) shareholders?

The filing certifies procedural compliance for delisting but does not include operational next steps for shareholders. It records the Exchange's action under 17 CFR 240.12d2-2; further shareholder instructions are not provided in this excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 02:56 PM EDT Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-224582

Issuer:	Iterum Therapeutics plc
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	Block 2 Floor 3, Harcourt Centre
	Harcourt Street
	Dublin	IRELAND	D02
Telephone number:					312-778-6070

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Ordinary Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-06-23	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.